Blog

Here’s what recruitment has to get right so willing patients reach a trial ready to enroll them. Every September, World Alzheimer's Day asks the world to remember the people behind a diagnosis and the families beside them. This year, the 2026 World Alzheimer Report puts clinical trials at the center of that conversation (Alzheimer's Disease International, 2026). For families living with dementia …

When electric motors replaced steam, factories ran them through the same belts built for the old engine. The power source changed. The process did not. Output stayed flat for forty years. Patient recruitment is repeating that history. More patient reach. More trial sites. Health-record mining. Now AI. New recruitment tools, same untested assumptions underneath.

Key Takeaways: How to Fix Clinical Trial Recruitment Bottlenecks More than 80% of clinical trials face delays due to patient recruitment challenges, making proactive planning essential for trial success. Structural barriers like geographic dispersion and strict eligibility criteria disproportionately impact enrollment at global sites. Underrepresented populations participate in trials at rates le…

More than a third of the patients your sites screen won't qualify. The average screen-failure rate across trials reached 36.3% ( Getz, 2019 ), and the fix is not more advertising; it's better targeting. That's the job of a clinical trial patient recruitment company: find patients who match your protocol, not patients who click. The right partner shortens your enrollment timeline. The wrong one bu…

An Interactive Web Response System (IWRS) is the web-based software clinical research sites use to randomize patients and manage investigational drug supply across a trial. It replaced the phone-based Interactive Voice Response System (IVRS) of the 1990s, and today most sponsors call this technology RTSM, Randomization and Trial Supply Management.

For years the industry quoted one number for a day of trial delay: $4 million in lost sales. It's wrong. That figure came from 1990s blockbuster math, and Tufts CSDD's 2024 analysis of 645 drugs put the real number at $500,000 to $800,000 a day ( Smith et al., 2024 ). Smaller, but it lands on top of the $55,716 a day it already costs to run a Phase III trial. Miss a Phase III timeline by three we…

See The Number That Surprised Five Sponsors Every enrollment plan starts as a set of assumptions dressed up as a forecast. The patient pool is deep enough. The eligibility criteria are workable. The interest is there. Each one feels solid because it matches what worked before. Then the study opens, and the number that arrives is not the number you planned around. The assumptions you never see are…

Adding sites is the fastest lever when enrollment stalls. Here is why it fails, and what to run first. When enrollment falls behind, expanding the network of clinical research sites is the lever sponsors can pull fastest. Site counts are visible, contractable, and reportable to leadership. The reflex makes sense. The real question is whether the market holds enough patients who can qualify, and m…

Patients clear your eligibility criteria, ask to be contacted, then vanish before they enroll. So why does a trial full of willing patients still miss its enrollment number? The answer sits in the steps between qualifying and enrolling, and those steps decide the number your forecast actually hits.

Finding the right patients for your clinical trial can feel like searching for a needle in a haystack. When enrollment stalls, timelines slip, and costs add up quickly. Patient recruitment services have become essential for pharmaceutical sponsors looking to connect with eligible participants faster and more efficiently.

Recruitment plans start with a headcount: this many patients with the condition, in these regions, so the trial is feasible. The math looks sound. The patients are real. Then enrollment stalls, and the assumption underneath the plan goes unquestioned: that a patient who exists is a patient the trial can reach. Those are two different things. And the gap between them is where feasible-on-paper stu…

Enrollment is behind, so the plan is to add clinical research sites. It feels like progress. It looks like a fix. It’s also the most expensive way to stay exactly where you are. Adding sites is a rational instinct. When the timeline slips and the board wants a number, expanding the network is the fastest lever available. But the instinct rests on an assumption: more sites means more patients, fas…

You selected your sites carefully. Six months in, enrollment is behind. The instinct: find better sites, bring more online. But site selection wasn’t the constraint. Narrow eligibility criteria were eliminating patients before a site could enroll them. In a Parkinson's Market Feasibility Test (a patient survey run before a single site opens) only 4% of 214 respondents qualified despite strong awa…

Market Feasibility helps test patient reach, understanding, and qualification signals earlier. Your patients don’t see a protocol. They see a headline, an image, a landing page, a screener question, a call, and a decision: Is this worth my time? That first interaction shapes what they understand before a site ever speaks with them. It tells them whether the study feels relevant, credible, and cle…

Clinical trials are moving toward faster data, faster signals, and faster decisions. The FDA recently announced real-time clinical trial proof-of-concepts and a proposed pilot program designed to help trial endpoints and data signals move to the agency in real time. The agency also opened a Request for Information, with comments due by May 29, 2026. That’s a major shift for clinical development. …

Are you still recruiting for “hypertension”… or for the full cardiometabolic reality your protocol actually requires? Hypertension used to be treated (and recruited) as a single-variable disease: elevated blood pressure. That model no longer reflects clinical reality. Today’s hypertension patient is increasingly part of a broader cardiometabolic profile: obesity, insulin resistance, type 2 diabet…

Clinical trial referrals don’t usually fail because patients aren’t interested. They fail because too many patients are pushed downstream before they’re truly qualified, informed, and ready for the next step. That creates a familiar pattern across studies: high referral volume, low referral quality, overloaded site teams, delayed enrollment, and preventable screening waste that gets blamed on rec…

Obesity remains one of the most commercially important areas in clinical development, but it is also one of the easiest places to misread recruitment performance. Strong demand can make enrollment look easier than it really is. In practice, the challenge is not simply generating interest. It is identifying the right patients early, educating them clearly, and moving them forward without adding av…

Smarter Matching, Faster Access: How AI Is Changing Clinical Trial Recruitment Finding the right clinical trial has long been a frustrating and time-consuming process for patients. Many spend hours searching through listings, trying to interpret complex eligibility criteria, only to discover they don’t qualify or never hear back. That experience is starting to change. AI in clinical trial recruit…

AI in Patient Recruitment: Signal, Limits, and the Operating Reality AI is already influencing patient recruitment. The real question is whether recruitment leaders are governing it or letting it run unchecked. In our latest whitepaper, AI in Patient Recruitment: Signal, Limits, and the Operating Reality, we move beyond hype and outline a practical operating model for sponsors, CROs, and research…